CEN Case Reports

, Volume 7, Issue 1, pp 127–131 | Cite as

A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I

  • Satoshi Takasaki
  • Akira Matsunaga
  • Kensuke Joh
  • Takao Saito
Case Report


Lipoprotein glomerulopathy (LPG) is a rare inherited disease characterized by histopathological features of lipoprotein thrombi in dilated glomerular capillaries and type III like hyperlipoproteinemia with heterozygous mutation of the apolipoprotein (apo) E gene. We herein present the case of a 50-year-old woman with LPG complicated by neurofibromatosis type 1 (NF1). To the best of our knowledge, this is the first report of a case of LPG complicated by NF1. On the other hand, she had not only a heterozygous apoE-Sendai mutation, which is one of the most frequent apoE variants in LPG patients, but also a rare isoform of ApoE5 (Glu3Lys). Although apoE mutation has been recognized as having a principal role in the pathogenesis of LPG, some other factors are assumed to be present in the pathogenesis of LPG, because many asymptomatic carriers of apoE variants are recognized. The coexistence of NF1 or apoE5 (Glu3Lys) allele might play a role as an additional factor in the development of LPG.


ApoE5 ApoE-Sendai Lipoprotein glomerulopathy Neurofibromatosis type I 




Compliance with ethical standards

Conflict of interest

All the authors have declared no competing interest.

Research involving human participants and/or animals

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

Written informed consent was obtained from the patient before the commencement of phenotype and gene analyses for apoE.


  1. 1.
    Saito T, Sato H, Kudo K, et al. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis. 1989;13:148–53.CrossRefPubMedGoogle Scholar
  2. 2.
    Oikawa S, Matsunaga A, Saito T, et al. Apolipoprotein E Sendai (arginine 145 ⟶ proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 1997;8:820–3.PubMedGoogle Scholar
  3. 3.
    Matsunaga A, Sasaki J, Komatsu T, et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int. 1999;56:421–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Saito T, Matsunaga A, Ito K, Nakashima H. Topics in lipoprotein glomerulopathy: an overview. Clin Exp Nephrol. 2014;18:214–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Kodera H, Mizutani Y, Sugiyama S, et al. A case of lipoprotein glomerulopathy with ApoE Chicago and ApoE (Glu3Lys) treated with fenofibrate. Case Rep Nephrol Dial. 2017;7:112–20.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Miyata T, Sugiyama S, Nangaku M, et al. Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney. J Am Soc Nephrol. 1999;10:1590–5.PubMedGoogle Scholar
  7. 7.
    Sam R, Wu H, Yue L, et al. Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis. 2006;47:539–48.CrossRefPubMedGoogle Scholar
  8. 8.
    Ordovas JM, Litwack-Klein L, Wilson PW, Schaefer MM, Schaefer EJ. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of ApoE1 and ApoE5 isoforms. J Lipid Res. 1987;28:371–80.PubMedGoogle Scholar
  9. 9.
    Feussner G, Scharnagl H, Scherbaum C, et al. Apolipoprotein E5 (Glu212 ⟶ Lys): increased binding to cell surface proteoglycans but decreased uptake and lysosomal degradation in cultured fibroblasts. J Lipid Res. 1996;37:1632–45.PubMedGoogle Scholar
  10. 10.
    Dong LM, Yamamura T, Yamamoto A. Enhanced binding activity of an apolipoprotein E mutant, APO E5, to LDL receptors on human fibroblasts. Biochem Biophys Res Commun. 1990;168:409–14.CrossRefPubMedGoogle Scholar
  11. 11.
    Wardell MR, Rall SC Jr, Schaefer EJ, Kane JP, Weisgraber KH. Two apolipoprotein E5 variants illustrate the importance of the position of additional positive charge on receptor-binding activity. J Lipid Res. 1991;32:521–8.PubMedGoogle Scholar
  12. 12.
    Van-Gils J, Harambat J, Jubert C, et al. Atypical hematologic and renal manifestations in neurofibromatosis type I: coincidence or pathophysiological link? Eur J Med Genet. 2014;57:639–42.CrossRefPubMedGoogle Scholar
  13. 13.
    Hyun JI, Min JW, Lee HM, Kim YK, Choi EJ, Song HC. Minimal change nephrotic syndrome showing complete remission after resection of a neurofibroma in a type I neurofibromatosis patient. Korean J Intern Med. 2017;32:186–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Afshinnia F, Vega-Warner V, Killen P. Focal segmental glomerulosclerosis in association with neurofibromatosis type 1: a case report and proposed molecular pathways. Clin Kidney J. 2013;6:208–10.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Koshikawa M, Mukoyama M, Mori K, et al. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol. 2005;16:2690–701.CrossRefPubMedGoogle Scholar
  16. 16.
    Gödel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 2011;121:2197–209.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ito K, Nakashima H, Watanabe M, et al. Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities. Nephrol Dial Transplant. 2012;27:3899–907.CrossRefPubMedGoogle Scholar
  18. 18.
    Koga T, Iwasaki H, Ishiguro M, Matsuzaki A, Kikuchi M. Losses in chromosomes 17, 19, and 22q in neurofibromatosis type 1 and sporadic neurofibromas: a comparative genomic hybridization analysis. Cancer Genet Cytogenet. 2002;15:113–20.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  1. 1.Department of Internal MedicineSaiseikai Yamagata Saisei HospitalYamagataJapan
  2. 2.Department of Laboratory MedicineFukuoka University School of MedicineFukuokaJapan
  3. 3.Department of PathologyTohoku University Graduate School of MedicineSendaiJapan
  4. 4.Sanko ClinicFukuokaJapan

Personalised recommendations